Consistent with those previous studies, gefitinib was demonstrated to show significantly reduced cytotoxic effects in CD133+ lung CSCs and increased the tumor sphere formation and proportion of CD133+ lung CSCs, suggesting that lung CSCs are resistant to gefitinib. The gene discussed is PROM1; the disease is neoplasm.